Literature DB >> 22866082

Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer.

Takumi Ochiai1, Kazuhiko Nishimura, Tomoo Watanabe, Masayuki Kitajima, Akinori Nakatani, Takashi Marusasa, Tadasuke Hashiguchi, Takayuki Uchida, Naoki Sakuyama, Tsuyoshi Sato, Kennji Kishine, Shunji Futagawa, Isao Nagaoka.   

Abstract

We previously reported the 5-fluorouracil (5-FU) sensitivity of cancer cells obtained from colorectal cancer (CRC) patients using the collagen gel droplet-embedded culture-drug sensitivity test (CD-DST). Multiple drug concentrations and contact durations, and the area under the concentration curve (AUC) and growth inhibition rate (IR) were combined, resulting in the AUC-IR curve, which was approximated to the logarithmic curve. Moreover, the individualized AUC(IR50), the AUC value which gives 50% growth inhibition, was calculated using the AUC-IR curve. This study aimed to identify responders/non-responders to 5-FU based on the individual AUC(IR50) obtained with CD-DST in order to establish individualized chemotherapy for CRC patients. The individual AUC(IR50) was calculated from each AUC-inhibition rate regression curve in all patients using the CD-DST. The cumulative distribution of the individual AUC(IR50) in CRC patients was evaluated. The cumulative distribution of the individual AUC(IR50) was regressed over the sigmoid curve (logarithmic scale). The approximate expression was almost exactly y=ab^exp(-cx) (a=0.9739, b=1.7096E-21, c=0.8990, the sum of square residuals, 0.0279). In the 80 cases examined, no notable change was observed in the regression curve when the number of patients increased. A standard curve was obtained describing responders to 5-FU among all CRC patients. From this standard curve, we ascertained that non-responders accounted for approximately 5% of all patients. Moreover, we were able to classify responders into good or intermediate responders to 5-FU. The standard curve describing response to 5-FU in CRC patients offers a useful tool in the establishment of individualized chemotherapy.

Entities:  

Year:  2011        PMID: 22866082      PMCID: PMC3410600          DOI: 10.3892/ol.2011.251

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis.

Authors:  Takumi Ochiai; Kazuhiko Nishimura; Hajime Noguchi; Tomoo Watanabe; Masayuki Kitajima; Nanami Konishi; Go Sato; Isao Nagaoka; Shunji Futagawa
Journal:  Anticancer Drugs       Date:  2007-01       Impact factor: 2.248

2.  Evaluation of the individual 50% inhibitory area under the concentration curve of 5-fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer.

Authors:  Takumi Ochiai; Kazuhiko Nishimura; Tomoo Watanabe; Masayuki Kitajima; Masataka Tsuji; Akinori Nakatani; Noboru Nakayama; Takashi Marusasa; Satomi Mashiko; Isao Nagaoka; Shunji Futagawa
Journal:  Mol Med Rep       Date:  2009 May-Jun       Impact factor: 2.952

3.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

4.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

5.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

6.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Authors:  Sharlene Gill; Charles L Loprinzi; Daniel J Sargent; Stephan D Thomé; Steven R Alberts; Daniel G Haller; Jacqueline Benedetti; Guido Francini; Lois E Shepherd; Jean Francois Seitz; Roberto Labianca; Wei Chen; Stephen S Cha; Michael P Heldebrant; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

7.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Authors:  Bruce J Giantonio; Paul J Catalano; Neal J Meropol; Peter J O'Dwyer; Edith P Mitchell; Steven R Alberts; Michael A Schwartz; Al B Benson
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

8.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Authors:  Howard S Hochster; Lowell L Hart; Ramesh K Ramanathan; Barrett H Childs; John D Hainsworth; Allen L Cohn; Lucas Wong; Louis Fehrenbacher; Yousif Abubakr; M Wasif Saif; Lee Schwartzberg; Eric Hedrick
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

10.  Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification.

Authors:  H Kobayashi; M Higashiyama; K Minamigawa; K Tanisaka; T Takano; H Yokouchi; K Kodama; T Hata
Journal:  Jpn J Cancer Res       Date:  2001-02
View more
  2 in total

1.  Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer.

Authors:  Masayoshi Inoue; Hajime Maeda; Yukiyasu Takeuchi; Kenjiro Fukuhara; Yasushi Shintani; Yasunobu Funakoshi; Soichiro Funaki; Takashi Nojiri; Takashi Kusu; Hidenori Kusumoto; Toru Kimura; Meinoshin Okumura
Journal:  Surg Today       Date:  2017-10-09       Impact factor: 2.549

2.  A modifiable microarray-based universal sensor: providing sample-to-results automation.

Authors:  Rubina Yasmin; Hui Zhu; Zongyuan Chen; Richard A Montagna
Journal:  Heliyon       Date:  2016-10-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.